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 Abstract - Farnesyltransferase inhibitors (FTIs) 
are a class of oral anti-cancer drugs currently tested 
in phase I-II clinical trials for treatment of 
hematological malignancies. The in vitro effects of 
various FTIs (alpha-hydroxyfarnesylphosphonic 
acid, manumycin-A and SCH66336) were tested on 
CD34+ KG1a cell line and in primary acute myeloid 
leukemia (AML) cells from 64 patients. By cell 
viability and clonogeneic methylcellulose assays, 
FTIs showed a significant inhibitory activity in 
CD34+ KG1a and primary bone marrow (BM) 
leukemic cells from 56% of AML patients. FTIs also 
induced activation of caspase-3 and Fas-independent 
apoptosis, confirmed by the finding that inhibition of 
caspase-8 was not associated with the rescue of FTI-
treated cells. We concluded that other cellular events 
induced by FTIs may trigger activation of caspase-3 
and subsequent apoptosis, but the expression of 
proapoptotic molecules, as Bcl-2 and Bcl-XL, and 
antiapoptotic, as Bcl-X(s), were not modified by 
FTIs. By contrast, expression of inducible nitric 
oxide synthase (iNOS) was increased in FTI-treated 
AML cells. Our results suggest a very complex 
mechanism of action of FTIs that require more 
studies for a better clinical use of the drugs alone or 
in combination in the treatment of hematological 
malignancies. 
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I.  INTRODUCTION 
 
 In recent years, several target therapies have 
revolutionized the approach to various hematological 
malignancies [1-3]. Farnesyltransferase inhibitors (FTIs), 
a class of oral active anti-cancer drugs, can competitively 
inhibit the farnesyltransferase (FTase) enzyme [4-9]. FTIs 
have been tested in several myeloid hematological 
diseases, as acute and chronic myeloid leukemia (AML, 
CML), because of their overexpression of Ras, MAPK, 
AKT and other FTase-dependent proteins involved in 
proliferation, survival and apoptosis [10-21]. The Ras 
proteins mediate signals from multiple cell surface 
receptors to the nucleus via different effector cascades 
[16-21]. Cytoplasmic Ras proteins need to be prenylated 
for fully biological functions. Farnesylation by the 
housekeeping enzyme FTase is the first required step in 
ras prenylation, enabling membrane anchor, ras activation 
and Ras-mediated activation of its downstream effectors 
[7-8,20-23]. FTase enzyme transfers a lipophilic farnesyl 
group from farnesyl diphosphate (FDP) to thiol group of 
cystein terminal portion of Ras, known as "CAAX- 
tetrapeptide motif", where "C" is cysteine, “A” is typically 
an aliphatic amino acid, and “X” is a serine or methionine 
as substrates of FTase. The other two additional steps of 
Ras prenylation are mediated by geranylgeranyl-
transferase type I and type II enzymes (GGTase I and II) 
[7-8,19-23]. As other G proteins, also Ras activation is 
mediated by membrane guanine nucleotide exchange 
factors (GNEF), which allow Ras to cycle between an 
inactive guanosine diphosphate(GDP)- to an active 
guanosine triphosphate (GTP)-binding status [24]. 
Besides, the intrinsic GTPase activity of Ras can revert the 
molecule back to its GDP-inactive form. Mutations in N- 
and K-ras genes, documented in 15-30% of AML patients, 
can constitutively active Ras, which appears to be also 
involved in leukemogenic transformation by bcr/abl in 
CML [25-29].  
In the last years, many FTIs have been identified, 
grouped into three main classes [30-31], and several of 
these have been evaluated preclinically. FDP analogues, 
as alpha-hydroxyfarnesyl phosphonic acid, beta-
hydroxyphosphonic acid derivatives, PD 169451 or RPR 
130401, can compete with FDP for the binding to FTase, 
but no specific antitumor effects have been described in 
vivo. CAAX competitive inhibitors, as L-778123, 
SCH66336 and R115777, are effective and selective 
FTase inhibitors in vitro and are currently testing in vivo. 
Bisubstrate inhibitors, as BMS 186511 and BMS-214662, 
combine the structural motifs of FPP and the CAAX 
tetrapeptide, linked by a phosphinyl or phosphonyl 
binding [30-31]. In particular, SCH66336 and R115777 
oral compounds are testing in phase I and II clinical trials 
in haematological malignancies, including AML, CML, 
juvenile myelomonocytic leukemia (JMML), 
myelodysplastic syndromes (MDS) and multiple myeloma 
(MM), myelofibrosis with myeloid metaplasia and elderly 
high-risk AML [25-29,32-38]. These preclinical trials 
have been shown a Ras-independent FTI activity [30-
31,39], probably because inhibition of Ras isoprenylation 
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may be not necessary for FTI antineoplastic effects [40-
41].  
The in vitro cytotoxic effects of various FTIs 
have been previously described, including the NO-
mediated apoptotic effects of SCH66336 in CML cells 
[42-43], but FTIs alone have shown only limited activity 
in AML and MDS patients [44-46]. The aim of the present 
study was to clarify the mechanism of action of FTIs, in 
order to explain the not enthusiastic results obtained in in 
vivo experiments. Consequently, we studied the in vitro 
effects of FTIs on apoptosis and growth of AML primary 
cells by blocking the downstream and upstream proteins 
of Ras-mediated apoptosis pathways. 
 
II.  METHODOLOGY 
 
Compounds blocking farnesyltransferase  
FTIs tested were: a nonpeptidic tryciclic 
competitive FTI SCH66336 (SCH) (a gift from Schering-
Plough Research Institute, Kenilworth, NJ); alpha-
hydroxy-farnesylphosphonic acid (α-HFPA) and 
manumycin-A (Man-A) (Sigma-Aldrich, St Louis, MO). 
These FTI compounds were stored at –20°C as 10 mM 
stocks in dimethyl sulfoxide (DMSO, Sigma-Aldrich). 
 
Cell lines and AML patient samples collection 
KG1a cells (American Type Culture Collection, 
Manassas, VA), were grown in RPMI 1640 supplemented 
with 10% heat-inactivated fetal calf serum (FCS), 2 mM 
L-glutamine, 100 U/mL penicillin, and 0.1 mg/mL 
streptomycin (complete medium, CM) at 37°C in 5% CO2. 
Heparinized BM samples were obtained from 11 normal 
BM transplantation donors and during diagnostic 
procedures from 64 patients (median age, 52 years; range, 
19-82; male/female, 28/36) with de novo (n=38) AML 
and AML with MDS-related features (n=26). Before 
sampling, informed consent was obtained according to the 
Declaration of Helsinki [47] and the procedures outlined 
by the ethical committee of our institution. Bone marrow 
mononuclear cells (BMMNCs) were isolated by density 
gradient centrifugation. After washing with phosphate-
buffered saline (PBS; Life Technologies, Carlsbad, USA), 
BMMNCs were resuspended in Iscove’s modified 
Dulbecco’s Medium (IMDM) supplemented with 10% 
heat-inactivated FCS. RPMI 1640, IMDM, PBS, FCS, L-
glutamine, penicillin, streptomycin, and lymphocyte 
separation medium were purchased from Life 
Technologies (Gaithersburg, MD).  
 
Suspension cultures 
KG1a and primary AML cells were placed  in 24-
well plates in RPMI containing 0.1% FCS for 12 and 2 
hours, respectively, before exposure to FTIs. For 
functional experiments, AML cells were preincubated for 
2 hours with the following reagents: caspase-3 inhibitor Z-
DEVD-FMK, caspase-8 inhibitor IETD-FMK, (all used at 
50 µM and purchased from Alexis, San Diego, CA), Fas-
receptor triggering inhibitor Fas:Fc (50 µM) (Alexis), 
iNOS inhibitor NG-monomethyl-arginine (500 µM) (γ-
MM-arg; Calbiochem, San Diego, CA). All experiments 
were repeated at least 3 times and each experimental 
condition was repeated at least in duplicate wells in each 
experiment. All the incubations were conducted at 37°C 
with 5% CO2. 
 
Proliferation assay 
In vitro sensitivity of KG1a and primary BM 
AML cells to FTIs was determined by plating 5 x 105 cells 
in RPMI 0.1% FCS and several dilutions of FTIs in 24-
well plates. Controls were performed using identical 
concentrations of the solvent used for FTIs. After 48h 
incubation, cell viability was determined by MTS (3-(4,5- 
dimethylthiazole- 2yl)- 5- (3- carboxymethoxyphenyl)- 2- 
(4- sulfophenyl)- 2H-tetrazolium, inner salt) and PES 
(phenazine ethosulfate) assay (CellTiter 96 AQueous One 
Solution Reagent) provided by Promega (Madison, WI, 
USA). Briefly, 20 l of CellTiter 96 AQueous One Solution 
Reagent was added to each well and incubated for 4 hours. 
The optical density (OD) was measured at 490 nm using a 
microplate spectrophotometer (Titertek Multiscan, 
BioRad, Hercules, CA). FTI effects were measured as 
percentage of inhibition of cell viability by the following 
equation: 1-[(OD treated well/mean OD control wells) x 
100], after background correction using blank wells. Each 
experiment was performed in triplicate. Values were 
expressed as mean value ± standard error of mean (SEM). 
The results were considered evaluable only if the control 
wells contained at least 70% of live AML cells after 48 h 
culture.  
 
Hematopoietic colony assay 
Short-term clonogenic progenitors were 
measured in methylcellulose (Stem Cell Technologies, 
Vancouver, CA). Isolated BMMNCs were plated in 
methylcellulose at 1 x 103 cells/ml concentration (35 mm 
dishes; 1 ml of medium/dish) in the presence of the 
following cocktail: 10 ng/mL IL-3, 50 ng/mL G-CSF, 50 
ng/mL GM-CSF, 20 ng/mL SCF, and 2 U/mL EPO. Anti-
Fas antibody (clone CH11, Amac) was used at 
concentrations ranging from 20-1000 U/ml to 1 µg/ml. 
Myeloid and erythroid colonies and clonogeneic 
aggregates of less than 50 cells, were counted as 
granulocyte-macrophage colony forming unit (CFU-GM), 
erythroid-burst forming unit (BFU-E) and clusters, 
respectively, after 14-day incubation. Each experiment 
was done in quadruplicate. Values were expressed as 
mean value ± standard error of mean (SEM).  
 
Apoptosis assays 
DNA fragmentation was measured after low 
molecular weight (LMW) DNA extraction from 2 x 106 
cells as previously described [48]. The high molecular 
weight DNA fraction was precipitated for 6 h in the 
presence of 5 mol/L NaCl and pelletted by high-speed 
centrifugation. The fragmented DNA was extracted, 
precipitated and electrophoresed as previously described 
[48].  
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Figure 1. FTI-induced inhibition of AML cell viability 
and clonal growth.  
Viability and cluster/colonies of AML cells were detected by 
MTT (A) and methylcellulose assays (B) measured by colony 
forming cell (CFC) assays. Each dot (subject studied) 
represents the percentage of inhibition of cell viability and 
colony formation by each FTI at the IC50 described in the text 
(control cultures were considered 100%). Horizontal bars are 
the mean values, and vertical bars are SEMs. Cumulative mean 
inhibition of cell viability and CFC ± SEM, as well as statistical 
analysis, are reported in the corresponding results section. 
Abbreviations, see text. 
Flow cytometric analysis of cellular DNA was 
performed using propidium iodide (PI) staining as 
previously described [48], adding 100 U/mL RNAse A 
(Boehringer Mannheim, Mannheim, Germany) during the 
incubation step. A minimum of 60,000 events was 
counted per sample. Apoptotic cell nuclei containing 
hypodiploid (fragmented) DNA were counted as a 
percentage of total population. 
 
Fas-R/FasL flow cytometry analysis  
Phycoerythrin (PE)-conjugated - CD34 (clone 
HPCA-1; Becton Dickinson [BD], San Jose, CA) was 
used to identify CD34+ cells. A fluorescein isothiocyanate 
(FITC)-conjugated - fragment of a murine anti-human 
CD95 (clone UB2; Amac, Westbrook, ME) combined 
with a PE-conjugated - CD34 was used to determine the 
expression of Fas-R on CD34+ cells. For Fas-L 
expression, BM cells were incubated with 
metalloproteinase inhibitor KB8301 (10 µmol/L, 
Pharmingen, San Diego, CA), PE-conjugated - CD34 
(BD) combined with a purified mouse anti-human Fas-L 
(IgG1, Nok1; Pharmingen) for 1 hour at 4°C. Then cells 
were incubated with FITC-conjugated goat anti-mouse 
IgG secondary antibody for 30 minutes at 4°C. Proper 
isotypic controls were used in all experiments.  
 
Detection of caspases 3 and 8 activities 
Activation of intracellular caspases was 
performed by flow cytometry using fluorogenic caspase-
specific substrates (DEVD-AFC for caspase-3, Alexis; 
and IETD-AFC for caspase-8, Pharmingen). Cells (1 x 
106) were treated with FTIs in the presence or absence of 
caspase-specific inhibitors for 24 hours, washed with PBS, 
and then resuspended in 50 µL of substrate buffer 
containing 10 mmol/L dithiothreitol (DTT) and 10 µL of 
the fluorogenic caspase-specific substrate supplemented 
with 5 µL of FCS. After centrifugation at 800g for 5 
minutes, cells were incubated at 37°C for 60 minutes. 
After incubation, cells were washed and acquired. At least 
10,000 events were analysed. Results were measured as 
fold increase in fluorescence relative to untreated control 
cells. 
 
Reverse transcription-polymerase chain reaction (RT-
PCR) for human iNOS RNA 
Total RNA was extracted from BMMNCs in 
TRIzol (Invitrogen, Carlsbad, CA), as previously 
described [48]. Human iNOS cDNA, after reverse 
transcription using an oligo d(T)16 primer, was amplified 
using the following primer pairs: 5' CGGTGCTGTATTT  
CCTTACGAGGCGAAGAAGG-3' and 5'-
GGTGCTGCTTGTTAGGAGGTCAAGTAAAGGGC-3'. 
Human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH, 5’-TTCACCACCATGGAGAAGGCT-3’ and 
5’-ACAGCCTTGGCAGCACCAGT-3’) was used as 
housekeeping gene. Reagents supplied in the Amplimer 
kit (Perkin Elmer, Foster City, CA) were used for the 
amplification reaction. PCR products were 
electrophoresed in 1.2% agarose gels and the bands were 
visualized after staining with ethidium bromide and UV-
light exposure.  
 
Immunoblotting of iNOS, Bcl2, BclXL and p53 
Treated AML cells were washed and lysed as 
previously described [48]. Concentrations were measured 
by colorimetric method (Biorad, Richmond, CO). A total 
of 100 µg of cell lysate, together with molecular weight 
markers (Amersham, Little Chalfont, UK) and iNOS 
positive mouse macrophages lysate (Transduction 
Laboratories, Lexington, KY) were fractionated by 7.5% 
SDS-polyacrylamide gel electrophoresis. PVDF 
membranes were prepared as previously described [48] 
and incubated with 2 µg/ml of mouse anti-iNOS, anti-
Bcl2, anti-p53, anti-BclXL and anti-BclXS antibodies 
(Transduction Laboratories, Lexington, KY) overnight at 
4°C. The reaction was revealed by incubating filters with 
horseradish peroxidase-conjugated goat anti-rabbit 
antibodies (BioRad, Richmond, CO) and developed by 
ECL (Amersham, Little Chalfont, UK) according to 
manufacturer’s specifications.   
 
Statistical analysis  
Two-tailed Student t-test was used for flow 
cytometric analysis and tissue culture experiments. p 
values  0.05 were considered statistically significant. 
 
III.  RESULTS 
 
FTI-induced growth inhibition of AML cells is partly 
related to apoptosis 
We first investigated the effects of FTIs on 
growth of KG1a AML cell line. In cell viability tests 
performed in logarithmic growth phase, KG1a cell 
survival was inhibited by all three FTIs in a dose 
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dependent manner. By linear regression analysis, we 
determined the 50% inhibitory concentration (IC50) after 
48 hour exposure to SCH, Man-A and α-HFPA. On an 
equimolar concentrations, SCH displayed more toxicity 
than Man-A (IC50 mean, 5 µM vs 50 µM, respectively; 
range, 1-20 µM vs 25-150 µM, respectively) and α-HFPA 
(IC50 mean, 100 µM; range, 75–150). The observed mean 
IC50 concentrations were used for next experiments.  
The inhibitory effects of SCH, Man-A and α- 
HFPA were significantly stronger in primary AML cells 
than normal marrow cells (mean inhibition % ± SEM, 
35±6 vs 13±5, respectively; p=0.03). We documented a 
FTI-mediated inhibition of cell viability >25% in 56% of 
AML patients (Fig. 1A). Similarly, by methylcellulose 
clonogeneic assays, colony and cluster growth inhibition 
>25% was observed in 64% of AML patients, whereas 
colony cells from normal BM cells were only weakly 
affected by FTIs exposure (mean inhibition % ± SEM, 
47.7±7 vs 15.5±1, respectively; p<0.001) (Fig. 1B). By 
allele-specific PCR, the presence of oncogenic N-Ras and 
K-Ras mutations were also investigated in primary cells 
from 30 AML patients. Oncogenic mutations of N-Ras 
were detected in 27% of AML subjects; by contrast, we 
did not observe K-Ras mutations in any AML cell sample. 
Indeed, FTI-mediated inhibition of cell growth was 
observed in both AML with and without N-Ras mutations 
(data not shown). 
To define whether the FTI-mediated growth 
inhibition of primary AML cells was associated to 
apoptosis, BM AML cells sensitive to FTI inhibition were 
exposed for 48 h to FTIs at IC50. By LMW DNA 
fragmentation analysis, AML cells showed the 
characteristic DNA ladder suggestive of apoptosis (Fig. 
2A). Flow cytometric detection of apoptotic hypodiploid 
DNA peak derived from treated BM AML cells confirmed 
the FTI-enhanced apoptotic cytotoxic effect (Fig. 2B). 
Indeed, percentages of apoptotic AML cells were 
significantly lower than those with cytolysis measured by 
cell viability assay (mean % ± SEM of cytolysis, 55.7±10; 
p=0.03). The parallel measurement of the number of 
apoptotic AML cells and viable cells from 10 AML 
patients carried by flow cytometry and cell viability 
assays showed that the percentages of apoptotic AML 
cells were significantly lower than those undergoing 
cytolysis (mean % ± SEM of apoptotic and viable AML 
cells, 32 ± 7 vs 51 ± 11, respectively; p = 0.03) (Fig. 2C). 
 
Caspase-3 and Fas-independent pathways are involved in 
FTI-mediated apoptosis of AML cells 
FTIs could induce caspase-3 activation by flow 
cytometric measurement of MFI after cleavage of the 
specific fluorogenic substrate DEVD-AFC (mean 
percentage of positive cells after 6 and 24h culture, 
25±4% and 38±4% vs 9±1% and 18±5%, FTI-treated and 
control AML cells, respectively; mean of 5 experiments). 
In addition, pre-incubation with caspase-3 inhibitor Z-
DEVD-FMK allowed to partially abrogate FTI-mediated 
caspase activation (mean % ± SEM after 24 h exposure to 
Figure 2. FTI-induced inhibition of AML cell proliferation is partly related to apoptosis. 
Agarose gel stained with ethidium bromide after electrophoresis of low molecular weight DNA from 12 representative BM 
AML patients exposed for 48 h to FTIs at the IC50 (A). A representative flow cytometric detection of apoptic hypodiploid DNA 
peak stained with PI from BM AML patient exposed to SCH (B). Percentages of viable cells and apoptotic cells simultaneously 
measured from 10 representative BM AML patients after exposure for 48 h to FTIs (C). Cumulative percentage of mean 
inhibition of cell viability and apoptotic cells, as well as statistical analysis, are reported in the corresponding results section. 
Abbreviations, see text. 
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FTI, 22±6; p=0.03) (Fig. 3A-B), and also to partially 
prevent FTI-mediated apoptosis (mean % of apoptosis ± 
SEM after FTI treatment, 36±4 vs 16.3±5, in absence and 
in presence of Z-DEVD-FMK respectively; p=0.01) (Fig. 
3C). 
Fas-R and Fas-L expression on AML cells 
exposed to FTIs was analysed by flow cytometry, but no 
variations were observed (21±4% and 23±8% in the 
absence and presence of FTIs, respectively) (Fig. 4A). 
Moreover, FTI–sensitive and FTI-resistant AML cells 
displayed similar expression of Fas-R (mean % ± SEM, 
39±4 vs 49±6, respectively; p=0.5) and Fas-L (mean % ± 
SEM, 49±4 vs 52±3, respectively; p=0.7) (Fig. 4B). No 
modifications of caspase-8 activity were detected in AML 
Figure 3. FTI-induced apoptosis in AML cells is mediated by activation of caspase-3.  
FTI induced activation of caspase-3. Caspase-3 activity in BM AML cells from a representative patient, cultured for 24 h in 
medium alone (untreated) or treated with FTI or with FTI + caspase-3 inhibitor Z-DEVD-FMK (50 µM), were measured by flow 
cytometry using the fluorogenic caspase-3 specific substrate DEVD-AMC (A). Caspase-3 is activated after FTI exposure in AML 
cells. Caspase-3 production in BM AML cells from a representative case, cultured for 6 and 24h in control medium (-FTI) or 
treated with FTI (+ FTI), was measured by flow cytometry using the cell-permeable FITC-labeled peptide FAM-VAD-FMK in 
combination with PI to differentiate dead from live cells (B). After 6 and 24 h of FTI exposure, 33% and 55% of live AML cells 
(B, bottom right panels) are positive for FAM-VAD-FMK, respectively. (Panel C) FTI-mediated apoptosis of AML cells is 
partially reverted by caspase-3 inhibition. Flow cytometric detection of apoptosis from a representative AML patient who showed 
in vitro susceptibility to FTI (SCH 1 µM) (C). Abbreviations, see text. 
Figure 4. FasR/FasL pathway is not 
involved in FTI-induced apoptosis in AML 
cells. 
Flow cytometric analysis of FasR and FasL 
expression in CD34+ AML cells from a 
representative case, untreated and treated with FTI 
(A). FTI-mediated inhibition of AML cell viability 
does not correlate with FasR and FasL expression on 
CD34+ AML cells. Cumulative mean ± SEM 
CD34+ Fas-R+ and C34+ Fas-L+ are reported (B). 
Caspase–8 is not activated by FTIs. AML cells 
untreated and treated with FTI after 48 h of culture. 
(C). AML cells were grown for 48 h with FTIs at 
IC50 and with FTIs + Fas-receptor triggering 
inhibitor Fas:Fc or caspase-8 inhibitor IETD-FMK 
(all used at 50 µM). AML cell viability was 
measured by colorimetric MTT assay. Columns 
represent cumulative mean ± SEM of cell viability 
of 5 experiments performed with all FTIs (D).  
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cells after 48 h FTIs exposure by flow cytometry and 
intracellular caspase staining (Fig. 4C). To further exclude 
the involvement of Fas-R/Fas-L system in FTI-mediated 
apoptosis, prior to exposure to FTIs, AML cells were 
preincubated for 2 h with selective Fas-R/Fas-L inhibitors. 
As expected, no variations were observed in FTI-mediated 
inhibition of cell growth and apoptosis after pretreatment 
with Fas-receptor antagonist and caspase-8 inhibitor 
(mean % ± SEM of cell growth after FTI exposure, 
41.6±3 and 43.3±3 without and with Fas:Fc vs 38±2 and 
39±1 without and with IETD-FMK vs 42.3±3 and 46.6±3 
without and with ZYVAD-FMK, respectively) (Fig. 4D). 
 
FTIs trigger iNOS expression in AML cells 
Unstimulated primary total AML BM cells 
expressed iNOS mRNA by PCR detection. Because iNOS 
expression in total BM AML cells might be related to 
non-leukemic cells, immature CD34+ KG1a cells were 
tested for the expression of iNOS mRNA after 48 h 
culture. A stronger amplification of iNOS was detected, 
and also after FTIs stimulation (Fig. 5A). Similarly, 
immunoblot of cell lysates showed lower levels of iNOS 
at baseline, and a 10-fold increased after FTIs stimulation 
in both primary total BM AML cells and KG1a cells (Fig. 
5B). Using the cell-permeable fluorescent indicator DAF-
2 DA, NO levels increased 40% after FTI exposure from 
basal levels detected in AML BM cells cultured in control 
medium without FTI (p<0.001), and γ -MM-arg partially 
blocked FTI-mediated NO production in CML cells (Fig 
5C). Inhibition of NO synthesis by pretreatment of AML 
cells with γ-MM-arg (500 µM), a competitive inhibitor of 
iNOS, did not affect the inhibitory effect on cell growth 
and apoptosis of FTIs (data not shown). However, when 
FTIs were used at IC10, γ-MM-arg partially prevented 
FTI effects (mean % ± SEM cell growth and apoptosis 
after FTI exposure, 31±2 and 21±4 vs 46±1 and 31±3 in 
absence and in presence of γ- MM-arg, respectively; 
p=0.01 and p=0.03) (Fig. 5C). 
 
FTI exposure may modify p53 but not Bcl-2 pathway in 
AML cells 
To explore whether FTI-induced apoptosis could 
be mediated by decreased expression of anti-apoptotic 
Bcl-2 and Bcl-X(L) or increasing in proapoptotic Bcl-
X(S) proteins, AML cells were exposed for 48 hours to 
FTIs or control medium and Bcl-2 or Bcl-X(L)/(S) were 
measured. Quantification of protein banding by 
densitometry did not document changes in Bcl-2 protein 
expression in KG1a as well as in four primary BM AML 
samples after FTI exposure as compared to control 
cultures (Fig. 6A). Similarly, the expression of  Bcl-X(L) 
and Bcl-X(S) did not show variations after FTI exposure  
Figure 5. FTI-induced inhibition of CML cell viability is mediated by NO pathway. 
FTIs induce iNOS mRNA signal amplification in KG1a and AML cells cultured for 48h. Ethidium bromide RT-PCR products 
(iNOS and GAPDH) are shown (A). FTIs cause increased expression of iNOS protein in KG1a cell line and 4 AML patients. 
Actin is used as control (B). γ-MM-arg partially preventes FTI-mediated apoptosis. Flow cytometric detection of apoptic 
hypodiploid DNA peak stained with PI from a CML patient treated with FTI (C).  
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(Fig. 5B). By contrast, in KG1a cells and few AML cases, 
an enhancement of p53 expression after FTI exposure was 
detected (Fig. 6C).  
 
IV.  DISCUSSION 
 
Despite the improvements in achieving prolonged 
remission for adult AML after cytotoxic induction 
chemotherapy or BM transplantation, the overall survival 
remains unsatisfactory, particularly for older patients [1-
3]. For this reason, new treatment approaches are required 
to improve the outcome in these patients. The 
upregulation of the classic mitogenic Ras/Raf/MAPK 
cascade has been documented in more than 30% of AML 
cases, due to mutations, overexpression or amplification 
of other oncogenic proteins with tyrosine kinase activity 
that may influence Ras pathways [10-21]. When 
farnesylation of Ras is blocked by FTIs in vitro, Ras is 
unable to anchor to cell membrane and its function is 
impaired (Fig. 7A-B) [16-21]. Various FTIs have already 
been evaluated in phase I-II and III clinical trials for the 
treatment of hematological malignancies, but contrasting 
results were reported, even though when associated to 
cytotoxic agents [25-29,32-38]. 
Here, the in vitro effects of FTIs were studied in 
AML cells. We have shown that FTIs showed a 
significant inhibitory activity on cell viability in CD34+ 
KG1a cell line and primary BM cells from 56% of AML 
patients. Indeed, only half of our AML patients showed 
increased sensitivity of cluster and colony growth after 
FTI exposure compared to normal marrow progenitor 
cells. Furthermore, the lack of response in the remaining 
half of AML patients could be related to the presence of 
mutations in FTase or other markers of resistance to FTIs, 
as p53 mutations, but more studies are needed to confirm 
this hypothesis [49-51].  
Preliminary data have excluded that FTI-
mediated inhibition of cell growth was Ras-mutations 
dependent, as FTIs induced inhibition of viability in AML 
cells with and without N-Ras mutations (Selleri et al., 
personal communication). As previously reported for 
CML cells, FTI-mediated cytotoxic effects in AML cells 
were partially related to enhanced apoptosis [48]. 
Although it has been reported that Ras-transformed cells 
showed Fas-R upregulation and higher Fas-related 
apoptosis after FTI-exposure [52-53], we documented a 
Fas-independent FTI-mediated apoptosis in AML cells. 
Moreover, FTI-mediated apoptosis seemed to be caspase-
3 dependent but caspase-8 independent as inhibition of 
caspase-8 was not associated with the rescue of FTI-
treated cells. These findings suggest that other cellular 
events induced by FTIs may trigger caspase-3 activation 
and subsequent apoptosis in AML cells. As the main event 
for caspase-3 activation is the release of cytochrome c 
from mitochondria, the expression of potential molecules 
modulating apoptosis via mitochondrial pathways were 
studied [54-55]. Expression of proapoptotic Bcl-2 and 
Bcl-X(L) and antiapoptotic Bcl-X(S) proteins were not 
modified by FTIs, except for the involvement of Bcl-2 
pathway in FTI-induced apoptosis in human AML cells. 
Another known mechanism that can concur in the 
inhibition of tumor growth is the macrophage-mediated 
NO release in the site of inflammation or in tumor 
environment, causing mitochondrial release of 
cytochrome c and apoptosis. In addition, it has been 
described that Ras inhibitors can increase NO-induced cell 
death [56-62]. In a similar manner, FTIs can induce 
apoptosis in CML cells, through cytochrome c release and 
caspase-3 activation, as previously documented [59,62]. 
As expected, FTIs also can induce iNOS expression in 
AML cells. Moreover, inhibition of NO synthesis partially 
abrogated the effects of FTIs on apoptosis suggesting that 
iNOS cascade may be only one of the possible 
mechanisms of FTI-mediated apoptosis in AML cells 
(Fig. 7 C-D). The enhancement of p53 expression in 
KG1a cell line and some AML cases suggested a complex 
mechanism of action of FTIs. Indeed, Moasser et al. has 
already reported a more susceptibility to FTIs in p53 wild-
type breast cancer cell lines [63].  
Figure 6. 
FTI exposure may modify p53 but not Bcl-2 pathway 
in AML cells 
Immunoblotting of Bcl2, BclXL and  BclXs from KG1a cells 
and total marrow cells of four AML patients cultured for 48 h 
in absence or in presence of FTIs, excludes the involvement of 
Bcl-2 pathway in FTI-induced apoptosis in human AML cells 
(A-B). Immunoblotting of p53 from KG1a cells and total 
marrow cells of four AML patients cultured for 48 h in absence 
or in presence of FTIs, shows the enhancement of p53, as 
quantified by densitometry scanning, in 2 out of 4 AML cases 
after FTI exposure (C). 
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Because caspases, iNOS and p53 play an 
important role in several intracellular pathways and can be 
triggered by several different extracellular signals, it is 
hard to clearly understand the FTIs mechanisms, also due 
to their aspecific action [54-62]. Several pathways are 
deregulated in cancers, as JAK/STATs or Syk/Btk, 
allowing proliferation and survival of tumor cells [64-67]. 
Indeed, it has been reported that over-activity of growth 
factor signaling pathways in breast cancer did not 
correlate with sensitivity to FTIs [63]. On the other hand, 
FTIs have shown contradictory results in MDS an AML 
patients, particularly in elderly and poor-risk AML [68-
72], but synergized actions were reported when FTIs were 
combined to tyrosine kinase inhibitors (TKIs) or other 
drugs, as simvastatin [73-77]. These findings suggest that 
FTIs can induce growth inhibition not only through 
apoptosis, but also interfering with proliferation pathways, 
enhanced when TKIs are used. Besides, the efficacy of 
ruxolitinib, a JAK1/2 inhibitor, or ibrutinib, a Btk 
inhibitor, has been described in several hematological 
malignancies, and more studies are ongoing [78-79]. For 
these reasons, to improve the therapeutic potential of FTIs 
alone or in combination with standard chemotherapy or 
new targeting therapies, it is important to better 
understand their mechanisms of action, as to investigate 
how they could impact on other pathways or vice versa. 
 
V.  CONCLUSION 
 
As already reported, in vitro FTIs effects on cell 
viability and apoptosis are caspase-3 and iNOS dependent 
in AML cells, and Fas-R/Fas-L or Bcl2 independent. But 
the involvement of p53 suggests a more complex 
mechanism in the susceptibility of FTI-mediated apoptosis 
in AML cells. It is also possible that FTIs may have only 
additive anti-neoplastic effects, requiring the combination 
with other anti-cancer agents to be effective in AML 
therapy. Our data open new questions about FTIs 
mechanism of action and their use in myeloid 
malignancies as single agents or in combination, in order 
to improve the outcome of hematological patients who 
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